All Pharma News
BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival

BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival
Nick Paul Taylor FIERCE BIOTECH
02 Jul 2024
Share Share
Eisai and Biogen launch Alzheimer`s drug Leqembi in China

Eisai and Biogen launch Alzheimer`s drug Leqembi in China
REUTERS
28 Jun 2024
Share Share
Eisai supports creation of Alzheimer’s podcast miniseries

Eisai supports creation of Alzheimer’s podcast miniseries
Nick Paul Taylor FIERCE PHARMA
12 Apr 2024
Share Share
EU regulator delays decision on Eisai-Biogen Alzheimer`s drug

EU regulator delays decision on Eisai-Biogen Alzheimer`s drug
REUTERS
23 Mar 2024
Share Share
LEQEMBI Approved for the Treatment of Alzheimer’s Disease in China

LEQEMBI Approved for the Treatment of Alzheimer’s Disease in China
PRESS RELEASE
10 Jan 2024
Share Share
Eisai`s Biologic Leqembi (lecanemab-irmb) Receives Approval in U.S.

Eisai`s Biologic Leqembi (lecanemab-irmb) Receives Approval in U.S.
FDA
06 Jan 2023
Share Share
Eisai Satisfies All-Case Study Requirement For Antiepileptic Agent Inovelon

Eisai Satisfies All-Case Study Requirement For Antiepileptic Agent Inovelon
EISAI
02 Nov 2022
Share Share
Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate

Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate
PRNEWSWIRE
11 Sep 2022
Share Share
Merck & Eisai Provide Update on Phase 3 LEAP-002 Trial

Merck & Eisai Provide Update on Phase 3 LEAP-002 Trial
BUSINESSWIRE
03 Aug 2022
Share Share
Eisai: MHLW Grants ODD in Japan to Mecobalamin Ultrahigh-Dose Formulation

Eisai: MHLW Grants ODD in Japan to Mecobalamin Ultrahigh-Dose Formulation
ASIAONE
27 May 2022
Share Share